Biotechnology: Biological Products (No Diagnostic Substances) stocks
Biotechnology: Biological Products (No Diagnostic Substances): 86 US common stocks over $300M. Rank 8 of 142 by the median 1-day move (+4.38%) on 6 Nov 2026, up 115 places from the session before. Median 1-day +4.38%, 1-month --, 6-month --. Biotechnology: Biological Products (No Diagnostic Substances) and the other stock industry groups are ranked on one page, each with its stocks and median returns.
+ Details
US common stocks over $300M (no ETFs, preferreds, notes, warrants or units), grouped by the industry the exchange screener lists. An industry with fewer than 3 goes to Other and its sector.
Medians of the group's stocks: 1-day is the screener's change for the session; 1-month and 6-month are a stock's close over its close 21 and 126 sessions back, from our end-of-day store (kept since 23 Oct 2026), for the stocks with both closes.
Rank: by today's median 1-day move until the store has a month of sessions; then by the median 1-month return.
Session: 6 Nov 2026.
Every stock in the group: type INDUSTRY BIOTECHNOLOGY-BIOLOGICAL-PRODUCTS-NO-DIAGNOSTIC-SUBSTANCES in the terminal.
Information only, not advice.
- AMGN Amgen Inc. 249.05B market cap, +0.03% on the session.
- GILD Gilead Sciences Inc. 207.00B market cap, −0.41% on the session.
- MRNA Moderna Inc. 101.48B market cap, +5.27% on the session.
- ARGX argenx SE American Depositary Shares 57.55B market cap, +3.63% on the session.
- RVMD Revolution Medicines Inc. 41.59B market cap, +8.24% on the session.
- BIIB Biogen Inc. 36.71B market cap, +1.81% on the session.
- BNTX BioNTech SE American Depositary Share 21.98B market cap, +1.92% on the session.
- EXEL Exelixis Inc. 16.98B market cap, +1.25% on the session.
- NBIX Neurocrine Biosciences Inc. 16.66B market cap, +3.05% on the session.
- HALO Halozyme Therapeutics Inc. 11.81B market cap, −15.72% on the session.